不同剂量艾司西酞普兰治疗广泛性焦虑患者的疗效及对5-HT、GABA含量的影响

doi:10.3969/j.issn.1671-7171.2023.09.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1145 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the efficacy of different dosages of escitalopram in the treatment of patients with generalized anxiety disorder (GAD) and its effect on plasma levels of 5-hydroxytryptamine (5-HT) and γ-aminobutyric acid (GABA).【Methods】A total of 86 patients with GAD admitted to our hospital were divided into the low,medium,and high dosage groups according to the different dosages of the treatment drug escitalopram,with initial dosages of 5 mg/d (low),10 mg/d (medium),and 20 mg/ d (high),respectively. The efficacy,Hamilton Anxiety Scale (HAMA) scores,Clinical Global Impression-Severity Scale (CGI-SI) scores,plasma levels of 5-HT and GABA,and the incidence of adverse reactions were compared among the three groups.【Results】The total effective rates in the medium-dosage group and high-dosage group were 93.10% (27/29) and 96.30% (26/27),respectively,which were significantly higher than 73.33% (22/30) in the low-dosage group (all P<0.05). There was no statistically significant difference in the total effective rate between the medium-dosage group and high-dosage group (P>0.05). HAMA and CGI-SI scores of the three groups after treatment were lower than those before treatment (P<0.05). The HAMA scores of the medium-dosage group and high-dosage group were significantly lower than that of the low-dosage group after treatment (P<0.05),but there was no statistically significant difference between the medium-dosage group and high-dosage group (P>0.05). The plasma levels of 5-HT and GABA in the three groups after treatment were higher than those before treatment (P<0.05). The plasma levels of 5-HT and GABA in the medium-dosage group and high-dosage group were significantly higher than those in the low-dosage group after treatment (P<0.05),but there was no statistically significant difference between the medium-dosage group and high-dosage group (P>0.05). The incidence of adverse reactions in the low-dosage group and medium-dosage group was 10.00% (3/30) and 17.24% (3/29),which were significantly lower than the 44.44% (12/27) in the high-dosage group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the low-dosage group and medium-dosage group (P>0.05).【Conclusion】Compared with low-dosage escitalopram treatment for patients with GAD,medium and high dosages can achieve better efficacy through effectively alleviating patients' clinical symptoms. And the medium-dosage group has a lower incidence of adverse reactions than the high-dosage group,with higher safety.

Key words： Anxiety/DT Anti-Anxiety Agents Serotonin Gamma-Aminobutyric Acid Treatment Outcome

Received: 15 October 2022

PACS:

R749.72

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAO Jing
	LI Juan

Cite this article:

CAO Jing,LI Juan. Efficacy of Different Dosages of Escitalopram in the Treatment of Generalized Anxiety Disorder Patients and its Impact on 5-HT and GABA Levels[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(9): 1303-1306.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.09.007 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I9/1303

[1] LAFRENIERE L S,NEWMAN M G. Exposing worry's deceit: percentage of untrue worries in generalized anxiety disorder treatment[J].Behavi Ther,2020,51(3):413-423.
[2] STRAWN J R,MILLS J A,SCHROEDER H,et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind,randomized,placebo-controlled study[J].J Clin Psychiatry,2020,81(5):4-11.
[3] TULISIAK A K,POWELEIT E,RAMSEY L A,et al. 5.7 cyp2c19 metabolizer status predicts escitalopram pharmacokinetics in adolescents with generalized anxiety disorder[J]. J Am Acad Child Adolesc Psychiatry,2019,58(10):247.
[4] 中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
[5] 张宇翔,郭蓉娟,耿东.基于关联规则和熵聚类算法的抑郁症肝郁脾虚证患者汉密尔顿抑郁焦虑量表研究[J].北京中医药大学学报,2018,41(9):781-786.
[6] 王海红,肖世富,李霞,等.临床疗效总评量表在阿尔茨海默病疗效评估中的应用探讨[J].上海精神医学,2009,21(5):269-272.
[7] 朱文静,陈致宇,梁燕. 两类抗精神病药物对精神分裂症患者的疗效及社会功能的影响[J].实用医学杂志,2016,32(22):3772-3775.
[8] 赵蓉蓉,石辉辉,尹延伟,等.艾司西酞普兰联合推拿治疗广泛性焦虑障碍的随机对照试验[J].中国心理卫生杂志,2022,36(6):476-480.
[9] 郭金涛,郭雅聪,牛好敏,等. 艾司西酞普兰治疗帕金森症合并焦虑和抑郁患者的疗效及对其认知功能的影响[J].国际精神病学杂志,2019,46(2):319-321.
[10] KOMULAINEN E,GLEREAN E,HEIKKIL R,et al. Escitalopram enhances synchrony of brain responses during emotional narratives in patients with major depressive disorder[J].Neuroimage,2021,237(2):118110.
[11] 廖波,甘桂荣,李彦,等.脑电生物反馈联合艾可西酞普兰在焦虑障碍治疗中的作用分析[J].中国医学创新,2019,16(29):52-55.
[12] 高永双. 不同初始剂量艾司西酞普兰治疗抑郁症伴主观性头晕的临床观察[J].中国病案,2018,19(5):106-109.
[13] 卢转娣,王要有.不同剂量艾司西酞普兰联合氯沙坦对高血压合并抑郁患者的疗效观察[J].安徽医学,2016,37(6):687-689.
[14] 董秋艳,白智华,刘鹏,等. 艾司西酞普兰联合唑吡坦对失眠障碍患者睡眠质量、焦虑抑郁状态及血清神经递质的影响[J].现代生物医学进展,2021,21(23):4496-4499.
[15] 丁楷模,李冰玥,张咪咪,等.艾司西酞普兰对抑郁模型大鼠脑内抑制性氨基酸变化的作用[J].中国全科医学,2021,24(20):2547-2554.
[16] 董秋艳,白智华,刘鹏,等.艾司西酞普兰联合唑吡坦对失眠障碍患者睡眠质量、焦虑抑郁状态及血清神经递质的影响[J].现代生物医学进展,2021,21(23):4496-4499.
[17] KONG W Q,DENG H Y,WAN J,et al. Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials[J].Front Pharmacol,2020,11(27):580858.